ABSTRACT
AIM: To evaluate the safety and efficacy of 10% intravenous immunoglobulin (IVIG; Flebogamma® 10% DIF) in individuals with chronic immune thrombocytopenic purpura (ITP). PATIENTS & METHODS: Patients aged 3-70 years, diagnosed with chronic ITP, received 1 g/kg IVIG over two consecutive days. RESULTS: 64 evaluable patients (51 adults, 13 children) with chronic ITP received IVIG. The primary efficacy end point (increased platelet counts from ≤20 × 109/l to ≥50 × 109/l by day 8) was achieved by 81.3% of patients; mean time to response was 1.7 days (all responders). Adverse events, mostly mild or moderate, were reported in 59 patients (92.2%). CONCLUSION: Flebogamma® 10% DIF administered over two consecutive days was safe and effective in adults and children with chronic ITP.
Subject(s)
Blood Platelets/pathology , Immunoglobulins, Intravenous/therapeutic use , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Leukocyte Count , Male , Middle Aged , Treatment Outcome , Young AdultABSTRACT
PURPOSE: The previous studies with Flebogamma(®) 5 % DIF intravenous immunoglobulin (IVIG) contained insufficient numbers of pediatric subjects to fully warrant a pediatric indication by the FDA. The objective of this study was to evaluate the efficacy, safety, and pharmacokinetics of Flebogamma® 5 % DIF for replacement therapy in children (age 2-16) with primary immunodeficiency diseases (PIDD). METHODS: IVIG was administered at eight clinical sites to 24 subjects with well-defined PIDD at a dose of 300-800 mg/kg every 21-28 days for 12 months. The pharmacokinetics endpoint in this study was the dose-adjusted increment of the serum IgG trough levels. RESULTS: The calculated serious bacterial infection rate was 0.05/subject/year. The incidence of adverse events considered potentially related to IVIG during or within 72 h after completing an infusion was within the FDA guidance threshold of <40 % at each time point. Dose-adjusted incremental IgG levels remained approximately equal to or slightly greater than pre-study IgG levels (between 800 and 1000 mg/dL throughout) when the subjects were treated with IVIG therapy other than Flebogamma(®) DIF 5 % indicating no evidence of a different pharmacokinetic profile in this pediatric population if compared to those profiles in previous Flebogamma studies in predominately adult populations. CONCLUSIONS: Flebogamma(®) 5 % DIF is efficacious and safe, has adequate pharmacokinetic properties, is well-tolerated, and maintains the profile of Flebogamma(®) 5 % for the treatment of children with primary humoral immunodeficiency diseases.
Subject(s)
Immunoglobulins, Intravenous/administration & dosage , Immunologic Deficiency Syndromes/drug therapy , Adolescent , Bacterial Infections/etiology , Child , Child, Preschool , Female , Humans , Immunoglobulins, Intravenous/adverse effects , Immunoglobulins, Intravenous/pharmacokinetics , Immunologic Deficiency Syndromes/diagnosis , Male , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: Flebogamma 10% DIF represents an evolution of intravenous immune globulin from the previous 5% product to be administered at higher rates and with smaller infusion volumes. Pathogen safety is enhanced by the combination of multiple methods with different mechanisms of action. OBJECTIVE: The objective of this study as to evaluate the efficacy, pharmacokinetics, and safety of Flebogamma 10% DIF for immunoglobulin replacement therapy in primary immunodeficiency diseases (PIDD). METHODS: Flebogamma 10% DIF was administered to 46 subjects with well-defined PIDD at a dose of 300-600 mg/kg every 21-28 days for 12 months. RESULTS: Serious bacterial infection rate was 0.025/subject/year. Half-life in serum of the administered IgG was approximately 35 days. No serious treatment-related adverse event (AE) occurred in any patient. Most of the potentially treatment-related AEs occurred during the infusion, accounting for 20% of the 601 infusions administered. CONCLUSIONS: Flebogamma 10% DIF is efficacious and safe, has adequate pharmacokinetic properties, and is well-tolerated for the treatment of PIDD.
Subject(s)
Immunoglobulins, Intravenous , Immunologic Deficiency Syndromes/therapy , Adolescent , Adult , Aged , Bacterial Infections/etiology , Child , Drug Dosage Calculations , Drug Evaluation , Female , Half-Life , Humans , Immunoglobulins, Intravenous/administration & dosage , Immunoglobulins, Intravenous/adverse effects , Immunoglobulins, Intravenous/pharmacokinetics , Immunologic Deficiency Syndromes/immunology , Male , Middle AgedABSTRACT
The purpose of the study was to evaluate the safety, efficacy, and pharmacokinetics of Flebogamma 5%, an immune globulin intravenous product, for replacement therapy in primary immunodeficient patients. The US Food and Drug Administration has proposed that the use of new products must result in < or =1 serious bacterial infection/subject/year, have acceptable safety and tolerability, and have pharmacokinetic properties similar to endogenous IgG and other commercially available immune globulin products. Flebogamma 5% was administered at seven clinical sites to 51 subjects aged 14-74 years with well-defined primary immunodeficiency diseases at a dose of 300-600 mg/kg every 21-28 days for 12 months. The calculated serious infection rate for the intent-to-treat population was 0.061/subject/year. The incidence of adverse events considered potentially related to Flebogamma 5%, and occurring during or within 72 h after completing the infusion was approximately 8%. The half-life of total IgG was 37 days. Flebogamma 5% is efficacious, safe, and well-tolerated, and does not put subjects at increased risk of adverse events other than those that could be reasonably expected in primary immunodeficient subjects who are receiving any immune globulin product.
Subject(s)
Immunoglobulins, Intravenous/administration & dosage , Immunologic Deficiency Syndromes/drug therapy , Adolescent , Adult , Aged , Half-Life , Humans , Immunoglobulins/blood , Immunoglobulins, Intravenous/adverse effects , Immunoglobulins, Intravenous/pharmacokinetics , Immunologic Deficiency Syndromes/complications , Incidence , Infections , Middle Aged , Treatment OutcomeABSTRACT
Octagam is an intravenous immunoglobulin preparation registered in Europe for treating primary immunodeficiency diseases (PID). The present clinical trial was designed to demonstrate that Octagam meets the minimal efficacy requirement of the U.S. Food and Drug Administration-that treatment should result in =1 serious infection/subject/year. The objectives of this clinical trial were to show that Octagam meets this requirement, and to confirm the safety of Octagam. Forty-six subjects with well-defined PID received Octagam (either 400-600 mg/kg every 28 days or 300-450 mg/kg every 21 days) for 12 months. The primary efficacy variable was the number of serious infections/subject/year. The estimated infection rate was 0.1 serious infections/subject/year. The half-life ( T (1/2)) of total IgG was 41 days. Adverse events potentially related to Octagam occurred in 5% of infusions, either during or within 30 min of the procedure. Octagam meets the Food and Drug Administration minimal requirement for efficacy. In addition, Octagam had a T (1/2) (IgG) comparable with published data, and was well tolerated. Octagam treatment is safe and resulted in 0.1 serious infections/subject/year in primary immunodeficient subjects.